{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-299475","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.953373+00:00","generated_at":"2026-06-21T08:59:01.658595+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"BridgeBio Pharma amends loan agreement, terminates tranche 2 commitments","bullets":["Second Amendment acknowledges prior prepayment satisfied mandatory prepayment requirement.","Certain budgeted expenses excluded from cash proceeds subject to mandatory prepayment.","Removed threshold amounts applicable to certain prepayment events.","Lenders' tranche 2 commitments terminated; royalty financing up to 10% of net sales permitted.","Royalty financing for Acoramidis remains exempt from prepayment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-299475","json":"https://secwatch.observer/filing/0001193125-22-299475.json","markdown":"https://secwatch.observer/filing/0001193125-22-299475.md","text":"https://secwatch.observer/filing/0001193125-22-299475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/0001193125-22-299475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/d423428d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:59:01.658595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eab452c17e38680229537796bd27d355dacf2513","claim":"BridgeBio Pharma, Inc. amended credit facility with U.S. Bank Trust Company, National Association (as administrative agent) and the Lenders.","evidence_excerpt":"Pursuant to the terms and conditions of the Second Amendment, the parties thereto agreed to, among other things: (1) acknowledge that the Company’s prior prepayment made with certain cash proceeds received in connection with that certain License, Development and Commercialization Agreement, dated as of May 11, 2022, by and among Navire Pharma, Inc., the Company and Bristol-Myers Squibb Company satisfied the mandatory prepayment requirement under the Amended Loan Agreement, on the terms and conditions specified in the Amended Loan Agreement, (2) permit certain budgeted expenses to be excluded from the definition of cash proceeds subject to Borrower’s mandatory prepayment obligations, on the terms and conditions specified in the Amended Loan Agreement, (3) remove certain threshold amounts applicable to certain prepayment events and (4) terminate the Lenders’ tranche 2 commitments.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/0001193125-22-299475-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association (as administrative agent) and the Lenders"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"61cf92afaead23d85d9f598e3457ca3fa9503050","claim":"BridgeBio Pharma, Inc. amended Second Amendment to Loan and Security Agreement with U.S. Bank Trust Company, National Association (as agent) and the lenders party thereto (effective 2022-11-30).","evidence_excerpt":"On November 30, 2022, BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”), by and among (i) U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, in its capacity as administrative agent (in such capacity, the “Administrative Agent”) and collateral agent (in such capacity, the “Collateral Agent”), (ii) the certain lenders party thereto (the “Lenders”), (iii) the Company, as a borrower, and (iv) certain subsidiaries of the Company, as guarantors (the “Guarantors”), pursuant to which the parties thereto agreed to amend the Loan and Security Agreement, dated as of November 17, 2021, as amended by the First Amendment to Loan and Security Agreement, dated as of May 12, 2022 (the “Existing Loan Agreement”, and amended by the Second Amendment, the “Amended Loan Agreement”), by and among the Company, Guarantors, Lenders, the Administrative Agent and the Collateral A","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/0001193125-22-299475-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association (as agent) and the lenders party thereto"},{"label":"Effective","value":"2022-11-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}